scholarly journals Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine

2022 ◽  
Vol Volume 17 ◽  
pp. 203-212
Author(s):  
Xiaoling Liu ◽  
Junhua Mai ◽  
Chaoyang Meng ◽  
Aldona J Spiegel ◽  
Wei Wei ◽  
...  
Keyword(s):  
Cancer Vaccine ◽  
Antitumor Immunity ◽  
Therapeutic Cancer Vaccine

scholarly journals 759 Development of an implantable artificial lymph node as a therapeutic cancer vaccine

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A807-A807
Author(s):  
Dixita Viswanath ◽  
Hsuan-Chen Liu ◽  
Corrine Ying Xuan Chua ◽  
Alessandro Grattoni
Keyword(s):  
T Cell ◽  
Cancer Vaccine ◽  
Cancer Vaccines ◽  
Antitumor Immunity ◽  
Tumor Antigens ◽  
Clinical Translation ◽  
Laboratory Animals ◽  
Host Immune System ◽  
Cancer Type ◽  
Therapeutic Cancer Vaccine

BackgroundPersonalized therapeutic cancer vaccines aim to target and reprogram the host immune system to achieve cancer eradication in situ. Cancer vaccines deliver two main components: immunostimulants (iS) and tumor antigens to reduce tumor burden with a robust T cell response; however, none have reached broad clinical success due to difficulty in vaccine administration, ex vivo cellular manipulation, low clinical efficacy and broad administrative barriers. While most efforts to date have focused on repeated bolus administrations, biomaterial-based vaccine strategies have led to promising clinical translation.MethodsIn light of these challenges, we have designed a clinically-viable platform-based vaccine strategy, termed the NanoLymph, to provide spatiotemporal elution of immunostimulants and tumor antigens locally to recruit and activate antitumor immunity for cancer eradication. Here, we aim to target the release of granulocyte macrophage colony stimulating factor (GM-CSF) and TLR-7/8 agonist Resiquimod (R848) to promote recruitment and activation of dendritic cells (DCs), a key player in antitumor cytotoxicity.ResultsWe demonstrate the NanoLymph as an structurally stable and biocompatible immunostimulatory niche for durable DC-driven tumor specific T-cell mediated cytotoxicity. Additionally, we demonstrate the NanoLymph’s ability to recruit and activate immune cells of interest, activating antitumor immunity against model antigen. Thus, we have provided the framework necessary to develop a personalized therapeutic cancer vaccine for tumor-specific T-cell mediated responses necessary to generate immunological memory.ConclusionsFuture studies will evaluate immunostimulant and tumor antigen biodistribution in vivo and further apply the NanoLymph in a tumor bearing model to effect antitumor cytotoxicity. Ultimately, we aim to develop a personalized platform applicable for every patient of any cancer type aimed at direct clinical translation.Ethics ApprovalThis study was approved by the Houston Methodist Research Institute (HMRI), according to protocols approved by the Institutional Animal Care and Use Committee (IACUC). HMRI’s Animal Welfare Assurance number is A4555-01. HMRI assures strict compliance with all federal regulations and guidelines involving the use of laboratory animals in biomedical research.

scholarly journals MAGE-A3 With Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine

JAMA Surgery ◽  
2014 ◽  
Vol 149 (5) ◽  
pp. 451 ◽  
Author(s):  
Ramesh B. Batchu ◽  
Oksana Gruzdyn ◽  
Ravindra B. Potti ◽  
Donald W. Weaver ◽  
Scott A. Gruber
Keyword(s):  
Cancer Vaccine ◽  
Therapeutic Cancer Vaccine ◽  
Cell Penetrating

scholarly journals An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

2018 ◽  
Vol 68 (5) ◽  
pp. 849-859 ◽  
Author(s):  
Amrita Singh ◽  
Georgia Koutsoumpli ◽  
Stephanie van de Wall ◽  
Toos Daemen
Keyword(s):  
Clinical Trial ◽  
Cancer Vaccine ◽  
Therapeutic Cancer Vaccine
Sign in / Sign up

Export Citation Format

Share Document